Juvenile dermatomyositis update.
Recent studies involving juvenile dermatomyositis indicate that the majority of affected children have symptoms suggestive of infection prior to disease onset, damage to skin and muscle each have a distinct pathophysiology, certain urinary muscle metabolites may be useful laboratory markers, and methotrexate used as first line therapy with corticosteroids is associated with greater height velocity and smaller increase in body mass index.
Lindsley
Carol B
CB
Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160-7330, USA. clindsle@kumc.edu
D015415:Biomarkers / Q000652:urine; D002648:Child; D003882:Dermatomyositis / Q000188:drug therapy / Q000453:epidemiology / Q000652:urine; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018482:Muscle, Skeletal / Q000378:metabolism; D015995:Prevalence; D011379:Prognosis
D015415:Biomarkers; D005938:Glucocorticoids; D007166:Immunosuppressive Agents